GSK plc (GSK)
| Market Cap | 71.26B |
| Revenue (ttm) | 41.97B |
| Net Income (ttm) | 3.37B |
| Shares Out | 4.08B |
| EPS (ttm) | 0.81 |
| PE Ratio | 21.17 |
| Forward PE | 8.67 |
| Dividend | $1.56 (4.41%) |
| Ex-Dividend Date | Nov 15, 2024 |
| Volume | 5,112,044 |
| Open | 35.19 |
| Previous Close | 35.36 |
| Day's Range | 35.06 - 35.52 |
| 52-Week Range | 31.72 - 45.93 |
| Beta | 0.33 |
| Analysts | Hold |
| Price Target | 47.00 (+33.26%) |
| Earnings Date | Feb 5, 2025 |
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled... [Read more]
Financial Performance
In 2023, GSK's revenue was 30.33 billion, an increase of 3.42% compared to the previous year's 29.32 billion. Earnings were 4.93 billion, a decrease of -67.05%.
Financial numbers in GBP Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for GSK stock is "Hold." The 12-month stock price forecast is $47.0, which is an increase of 33.26% from the latest price.
News
Influenza Vaccines Market Analysis 2025-2032: GlaxoSmithKline's Influenza Vaccines Sales Declined in 2024, Driven by Competitive Pressure and Volume Phasing in the US and Lower Demand
Dublin, Jan. 27, 2025 (GLOBE NEWSWIRE) -- The "Influenza Vaccines Market, Persons Vaccinated, By Segment - Vaccine Type, Indication, Technology, Route of Administration, End-user, Geography, Company A...
Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?
Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and Goliath dynamic” in 2024, report says.
Hallucinations in AI: How GSK is addressing a critical problem in drug development
Hallucinations are a persistent problem in healthcare. Here's how GSK is using test-time compute scaling to improve its gen AI systems.
GSK plc (GSK) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
GSK plc (NYSE:GSK) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 10:30 AM ET Company Participants Emma Walmsley - CEO Luke Miels - Chief Commercial Officer Tony Wood - Chief Scientif...
Healthcare sector poised for rebound in 2025
The JPMorgan Healthcare Conference is a place where deals happen. As the conference kicked off, deals were announced from Eli Lilly (LLY), Johnson & Johnson (JNJ), and GSK (GSK).
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...
GSK CEO on acquisition of biotech firm IDRx
Emma Walmsley, GSK CEO, joins 'Money Movers' to discuss the company's deal to acquire IDRx, the impact of Robert F. Kennedy Jr.'s administration position, and much more.
Drugmakers rush to sign deals on first day of industry conference
Drugmakers signed deals worth at least $18 billion in combined value on Monday, the first day of the healthcare industry's top conference in San Francisco.
GSK to buy US biotech firm IDRx for up to $1.15 billion
British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of tumour.
GSK Enters Agreement to Acquire IDRx, Inc.
PLYMOUTH, Mass.--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, clinical-sta...
GSK and Pfizer's RSV vaccines to carry warnings of neurological disorder risk
GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing a rare neurological disorder, the U.S. Food Drug Administration said on Tu...
GSK's cancer drugs meet progression-free survival goal in late-stage trial
GSK said on Friday the addition of its cancer drug Jemperli to both standard of care chemotherapy and Zejula maintenance improved survival in patients with advanced ovarian cancer without the disease ...
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis
FOR IMMEDIATE RELEASE Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis
GSK's drug combo shown to cut risk of death by 42% in type of blood cancer
British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the risk of death by 42% in multiple myeloma, a common type of blood cancer, at o...
Final Trades: Oracle, Vertiv Holdings and GSK
The Investment Committee give you their top stocks to watch for the second half.
GSK, China's Zhifei Expand Shingles Shot Collaboration
GSK extended its collaboration with Zhifei to commercialize its shingles vaccine Shingrix in China until 2034.
GSK expands deal with China's Zhifei to explore RSV vaccine collaboration
GSK said on Thursday it has expanded its agreement with China's Zhifei to explore a collaboration with the Chinese vaccines company on the British drugmaker's respiratory syncytial virus (RSV) vaccine...
GSK's RSV vaccine gets Japan approval for adults aged 50 to 59
GSK said on Friday that its respiratory syncytial virus (RSV) vaccine has received approval in Japan for expanded use in adults aged between 50 and 59, who are at increased risk of severe RSV disease.
GSK share price is imploding: is it safe to buy the dip?
The GSK share price has been in a strong freefall after peaking at 1,785p in September. Most recently, the GSK stock retreated for five consecutive weeks and reached its lowest level since October las...
GSK drug meets main goal in late-stage study to treat relentless itch
British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat patients with a so-called relentless itch associated with a rare autoimmun...
As Drug Maker Stocks Fall, Pressure Builds On PhRMA To Derail RFK, Jr.
Stocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Donald Trump announced that he wants vaccine skeptic Robert F. Kennedy Jr. to lead the U.S. De...
GSK plc (GSK) Guggenheim's Inaugural Healthcare Innovation Conference (Transcript)
GSK plc (NYSE:GSK) Guggenheim's Inaugural Healthcare Innovation Conference November 12, 2024 2:00 PM ET Company Participants Emma Walmsley - Chief Executive Officer Conference Call Participants Seamu...
Pharma shares hit as Trump picks RFK Jr to lead health department
Choice of vaccine critic knocks some of world's biggest drugmakers including Moderna, AstraZeneca and GSK